机构名称：
¥ 1.0
摘要：患有2型糖尿病的人有发生进行性糖尿病肾脏疾病（DKD）和末期肾脏衰竭的风险。高血压是糖尿病患者蛋白尿，肾功能受损，终末期肾脏疾病和心血管疾病的主要风险因素。Slowing progression of kidney disease and reducing cardio-vascular events can be achieved by a number of means including the targeting of blood pressure and the use of specific classes of drugs The use of Renin Angiotensin Aldosterone System (RAAS) blockade is effective in preventing or slowing progression of DKD and reducing cardiovascular events in people with type 2 diabetes, albeit differently according to the stage of DKD.然而，事实证明，新兴疗法（例如非甾体类选择性矿物皮质激素拮抗剂（Finerenone）已被证明可以降低血压，并进一步降低2型糖尿病患者的DKD和心血管疾病进展的风险。这种共识回顾了当前的证据，并提出了在英国糖尿病肾脏疾病管理中使用罚款的建议。
糖尿病肾脏疾病管理中的Finerenone
主要关键词
相关文件推荐
